Reading SENS? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track SENS free→Reading SENS? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track SENS free→NASDAQHealth CareMedical DevicesSnapshot 2026-06-15
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
Recent financial performance is weak. Earnings quality cannot be assessed since the company was unprofitable over the past year. Management's recent track record has been unsteady, with frequent changes. Risk is elevated, and the sector backdrop is a headwind. Compared with sector peers, SENS is below typical. Peer multiples imply a price about 49% below where it trades (it looks expensive on this basis). The read is expensive, growth-justified, as it is rich on today's multiple, but the three-year horizon reads cheaper once expected earnings growth is included. The outlook hinges on sector trends and guidance changes. This read is provisional.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 2 valuation methods, at three horizons. Current price $7.24. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $7.24 SENS trades at 8× p/s — 2.8× the 3× p/s peer median. The market is re-rating it beyond its own range; our $3.83 fair value is low-confidence here. Analysts: $8.00–$14. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
The market is pricing in roughly 89% near-term growth, ahead of our forecast of about 66%. This describes what's priced in, not a forecast of the move.
TTM earnings are negative, so the read leans on sales- and cash-flow-based methods rather than P/E. This is a data condition, not a forward call.
Flags: expensive valuation, a turbulent sector regime (Heating).
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 0 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 55% of the time over the next year (vs 54% for the rest of the cohort, n=2391).
Over the trailing year it converted 0.86x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, long-term interest rates, real (inflation-adjusted) rates, Fed net liquidity.
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
EPS estimate $-0.65 → $-0.62 (+4.6% / 30d). 5 raised, 1 cut, 6 covering analysts.
0 upgrades, 0 downgrades / 30d. 57% of analysts rate Buy.
1 positive, 0 negative / 30d. See F4 management tile for the event list.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
On a typical day, $10k can swing ±$190.
How much price usually moves either way.
On a bad day, this stock has moved -$707.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $5,719.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
No material changes since the prior snapshot.
as of 2026-06-15
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: Revenue growth is on track, and updates could signal continued success or potential challenges. Investors want to see if growth can be sustained.
Confirms:Revenue growth reported above 15% year over year in the next earnings report.
Disproves:Revenue growth reported below 5% year over year.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for SENS yet.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
Other Events. Closing of Local Asset Purchase Agreements As disclosed in the Current Report on Form 8-K filed by Senseonics Holdings, Inc. (the “ Company ”) with the Securities and Exchange Commission on March 12, 2026, the Company, Senseonics, Incorporated (together with the Company and its affiliates, the “ Purchaser Parties ”) and Ascensia Diabetes Care Holdings AG (the “ Seller ” and together with its affiliates, the “ Seller Parties ”) entered into a series of local asset purchase agreem…
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
$8.00 – $14.00 (median $9.00) · 3 analysts · as of 2026-05-12
For similar setups historically (n=2,301): about 43% saw a 20%+ drawdown, and roughly 77% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Looks more expensive than peers.
Self-history needs ~20 months of data.
Trailing four: 2025-Q1, 2025-Q2, 2025-Q3, 2026-Q1
A side-by-side read on sector standing, valuation, and risk versus Health Care Equipment.
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
SENS Senseonics Holdings Inc | Below typical Show detailsSector percentile: 24 of 100 | expensive | elevated |
ABT Abbott Laboratories | Above typical Show detailsSector percentile: 94 of 100 | fair | moderate |
ISRG Intuitive Surgical | Above typical Show detailsSector percentile: 94 of 100 | expensive | moderate |
SYK Stryker Corporation | Above typical Show detailsSector percentile: 71 of 100 | fair | moderate |
MDT Medtronic | Above typical Show detailsSector percentile: 89 of 100 | fair | moderate |
15 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated volatile grew net income 43% of the time over the next year (vs 57% for the rest of the cohort, n=600).
Not investment advice. As of 2026-06-15.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-15.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Senseonics is focusing on growth through strategic acquisitions.
Senseonics aims to improve its operating income, which has been negative.
Senseonics is focused on increasing its revenue over time.
Why it matters: The acquisition could help Senseonics grow and improve its market position. Investors will look for details on how this impacts revenue and operations.
Confirms:A press release will explain how the acquisition will affect revenue.
Disproves:There are no new updates. No negative comments about the acquisition's benefits.
Why it matters: Better operating income is important for Senseonics. Good numbers may show better cost control.
Confirms:Operating income is rising, increasing by at least 10% each quarter.
Disproves:Operating income keeps going down or stays the same.
Results of Operations and Financial Condition. On May 7, 2026, Senseonics Holdings, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2026, as well as information regarding a conference call to discuss these financial results and the Company’s recent corporate highlights and outlook. This press release has been furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by this reference. The information in…
Entry into a Material Definitive Agreement. On May 1, 2026, Senseonics Holdings, Inc. (the “Company”) together with several of its wholly-owned subsidiaries (collectively, “Senseonics”) entered into a Second Amendment to Loan and Security Agreement (the “Second Amendment”) with the several financial institutions or entities party thereto (collectively, the “Lenders”) and Hercules Capital, Inc., a Maryland corporation (the “Agent”), in its capacity as administrative agent and collateral agent…
of this report; and · provide for up to an additional $85.0 million future tranches of term loans, subject to the Company’s satisfaction of certain terms and conditions and, with respect to the last $60.0 million uncommitted tranche, future lender investment committee approval. After giving effect to the amended facility and the funding of Tranche 2 and Tranche 3A, as of December 31, 2025, the Company’s as adjusted total debt outstanding under the Loan and Security Agreement would have been a…
Results of Operations and Financial Condition. Although the Company has not finalized its full financial results for the quarter ended March 31, 2026, it expects to report the following selected financial information as of and for the quarter ended March 31, 2026: · revenue of approximately $11.7 million; · gross profit of approximately $6.4 million; · gross margin of approximately 54%; · net loss between $31 million and $33 million; · cash, cash equivalents, short-term investments and restri…